The restoration of good metrics of muscle physical function and mobility achieved by reprogramming myosin enzymatic activity via oral administration of a small-molecule modulator raises hope for patients with MPD1 and related MYH7 distal myopathies. The gene discussed is MYH14; the disease is distal myopathy.